GlassScriptPhysician profile
Emanuel S Chris
NPI 1326086547
$12,430.75
in general payments reported to CMS, 2019-2025
30 companies · $3,203 in 2025
The $3,203 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,407 · 2020: $322 · 2021: $1,303 · 2022: $1,608 · 2023: $2,101 · 2024: $2,487 · 2025: $3,203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,621 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,621.17 |
| Education | $169.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,062.25 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $1,520.38 | 2019-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,177.40 | 2021-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $1,027.54 | 2019-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $941.16 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Lundbeck LLC | $934.59 | 2019-2025 | Rexulti |
| Alkermes, INC. | $624.62 | 2019-2025 | Aristada, Lybalvi |
| Tris Pharma INC | $506.37 | 2022-2025 | Dyanavel Xr |
| Corium, LLC | $495.59 | 2022-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $477.32 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $450.60 | 2019-2025 | Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $442.43 | 2019-2025 | Trintellix |
| Axsome Therapeutics, INC. | $430.41 | 2022-2025 | Auvelity, Sunosi |
| Sunovion Pharmaceuticals INC. | $343.83 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $234.62 | 2023-2025 | Qelbree, Qelbree |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $179.18 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $121.29 | 2024-2025 | Cobenfy |
| Indivior INC. | $93.56 | 2019 | |
| Vertical Pharmaceuticals, LLC | $63.07 | 2025 | Relexxii |
| Ironshore Pharmaceuticals INC. | $41.65 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $36.52 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $36.00 | 2019 | |
| Shire North American Group INC | $35.52 | 2019 | |
| Bausch Health US, LLC | $24.71 | 2021 | |
| Noven Therapeutics, LLC | $24.66 | 2024 | Secuado, Xelstrym |
| Sage Therapeutics, LLC | $24.24 | 2025 | Zurzuvae |
| Neos Therapeutics, LP | $23.26 | 2024 | Adzenys Xr-Odt |
| Collegium Pharmaceutical, INC. | $22.06 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $20.24 | 2023 | Quviviq |
| Rhodes Pharmaceuticals L.P. | $15.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emanuel Chris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.